Shots:

• The approval is based on the P-III REACH3 study evaluates the safety & efficacy of Jakafi vs BAT in patients ≥12yrs. with steroid-refractory chronic GVHD after the failure of 1 or 2 lines of systemic therapy
• The results showed that the patients treated with Jakafi led to significantly improved outcomes across a range of efficacy measures- ORR (49.7% vs 25.6%) @24wks. Additionally- ORR (70% vs 57%) through Cycle 7 Day 1. The results were published in the NEJM
• Jakafi is a JAK1/JAK2 inhibitor & marks 4th FDA-approved indication. Patients treated with Jakafi have access to the IncyteCARES program that offers patient support- including financial assistance- education & resources

Click here  | Ref: Businesswire | Image: List 23